Securities code: 300017 securities abbreviation: Wangsu Science & Technology Co.Ltd(300017) Announcement No.: 2022-010 Wangsu Science & Technology Co.Ltd(300017)
Announcement on the progress of using self owned funds to purchase financial products
The company and all members of the board of directors guarantee that the contents of the announcement are true, accurate and complete without false records, misleading statements or major omissions.
Wangsu Science & Technology Co.Ltd(300017) (hereinafter referred to as "the company") deliberated and adopted the proposal on adjusting the use of its own idle funds to purchase financial products at the fifth meeting of the Fifth Board of directors held on October 30, 2020 and the second extraordinary general meeting of shareholders held in 2020 on November 17, 2020, and agreed that on the premise of ensuring the daily operation capital demand and capital safety of the company, The investment scope and investment period of the company and its subsidiaries using their own idle funds to purchase financial products are adjusted as follows: (1) the total amount of low-risk financial products that the company and its subsidiaries can purchase is adjusted to RMB 3700 million (including equivalent foreign currency), and the investment period of a single financial product shall not exceed 12 months; (2) In addition, the total amount that the company and its subsidiaries can purchase financial products with risk level no higher than medium risk is RMB 300 million (including equivalent foreign currency). The deadline of the above investment period is April 9, 2022.
The 10th meeting of the 5th board of directors held on April 12, 2021 and the 2020 annual general meeting of shareholders held on April 23, 2021 considered and approved the proposal on extending the investment period of purchasing financial products with its own idle funds. After deliberation, it is agreed that on the premise of ensuring the daily operation capital demand and capital security, the amount and investment scope of the company and its subsidiaries using their own idle funds to purchase financial products will remain unchanged, and the investment period will be extended to be valid for three years from the date of deliberation and approval by the 2020 annual general meeting of shareholders.
On February 21, 2022, the 20th meeting of the 5th board of directors held by the company considered and adopted the proposal on adjusting matters related to the purchase of financial products with its own idle funds. Agree that the company and its subsidiaries use their own funds with an amount of no more than RMB 4 billion (including equivalent foreign currency) to purchase fund management products issued by financial institutions such as commercial banks, securities companies, fund companies or trust institutions without affecting normal production and operation and effectively controlling risks, Among them, 3.5 billion (including equivalent foreign currency) of its own funds are limited to the purchase of financial products with risk level no higher than medium and low risk. The term of a single financial product shall not exceed 12 months. Within the above limits, the funds can be recycled and used on a rolling basis. This matter needs to be deliberated and approved by the general meeting of shareholders of the company, and the investment period is from
Valid within 12 months from the date of deliberation and approval by the general meeting of shareholders of the company (calculated based on the time point of purchasing financial products).
From December 18, 2021 to February 21, 2022, the company purchased financial products with its own funds,
The relevant matters are hereby announced as follows:
1、 Basic information of financial products
Unit: RMB 10000
Name of investor trustee nature of related products risk entrusted wealth management fund start date end date annualized income relationship amount profit rate
Citibank, a subsidiary, has no structured deposits in US dollars, with low risk 3170.05 2021 / 12 / 24 2022 / 2 / 28 1.30%
Citibank, a subsidiary, has no USD structured deposits and low risk 2536.04 2021 / 12 / 24 2022 / 6 / 29 1.50%
Subsidiary KB securities has no usdrp products, low risk 1268.02 2021 / 12 / 29 - 0.30%
Wangsu Science & Technology Co.Ltd(300017) CITIC Trust no low risk financial products low risk 5000.00 2022 / 1 / 4 - t + 1
Wangsu Science & Technology Co.Ltd(300017) Bank Of Ningbo Co.Ltd(002142) no USD structured deposit, low risk 3804.06 2022 / 1 / 6 2023 / 1 / 10 2.03%
Wangsu Science & Technology Co.Ltd(300017) Bank Of Ningbo Co.Ltd(002142) no USD structured deposit low risk 4438.07 2022 / 1 / 6 2023 / 1 / 10 1.88%
Wangsu Science & Technology Co.Ltd(300017) China Everbright Bank Company Limited Co.Ltd(601818) no low-risk financial products low risk 3000.00 2022 / 1 / 6 t + 1 3.60%
Subsidiary Xinhan financial investment no RP products, low risk 1.83 2022 / 1 / 10 - 0.70%
Wangsu Science & Technology Co.Ltd(300017) Ping An Trust has no low-risk financial products. Low risk 5000.00 2022 / 1 / 10 2023 / 1 / 10 5.40%
Wangsu Science & Technology Co.Ltd(300017) China Everbright Bank Company Limited Co.Ltd(601818) no low risk financial products low risk 4000.00 2022 / 1 / 11 T + 7 3.65%
Subsidiary KB securities no RP products, low risk 211.68 2022 / 1 / 12 - 0.10%
Wangsu Science & Technology Co.Ltd(300017) CCB trust has no low-risk financial products. Low risk 5000.00 2022 / 1 / 13 2023 / 1 / 9 4.40%
Wangsu Science & Technology Co.Ltd(300017) China Everbright Bank Company Limited Co.Ltd(601818) no low risk financial products low risk 3000.00 2022 / 1 / 17 T + 1 3.60%
Wangsu Science & Technology Co.Ltd(300017) China Construction Bank Corporation(601939) no USD structured deposit low risk 5072.08 2022 / 1 / 18 2023 / 1 / 18 1.86%
Wangsu Science & Technology Co.Ltd(300017) Ping An Trust has no low-risk financial products. Low risk 6000.00 2022 / 1 / 21 2023 / 1 / 21 5.30%
Citibank, a subsidiary, has no USD structured deposits and low risk 3170.05 2022 / 1 / 20 2022 / 4 / 25 1.20%
Citibank, a subsidiary, has no USD structured deposits and low risk 6340.10 2022 / 2 / 2 2023 / 2 / 1
Wangsu Science & Technology Co.Ltd(300017) CITIC Trust has no low-risk financial products. Low risk 3300.00 2022 / 2 / 8 - t + 1
Wangsu Science & Technology Co.Ltd(300017) China Everbright Bank Company Limited Co.Ltd(601818) no low risk financial products low risk 3000.00 2022 / 2 / 11 T + 1 3.60%
Subsidiary Xinhan financial investment no RP products, low risk 1.83 2022 / 2 / 14 - 0.95%
Wangsu Science & Technology Co.Ltd(300017) CCB trust no low-risk financial products low risk 5000.00 2022 / 2 / 16 2023 / 2 / 10 4.40%
Wangsu Science & Technology Co.Ltd(300017) China Construction Bank Corporation(601939) no USD structured deposit low risk 4438.07 2022 / 2 / 16 2023 / 2 / 16 2.21%
Wangsu Science & Technology Co.Ltd(300017) BNP Paribas has no RMB structured deposit with Principal Guaranteed floating rate of 5000.00 2022 / 2 / 16 2023 / 2 / 14
Movable income
Wangsu Science & Technology Co.Ltd(300017) Ping An Trust has no low-risk financial products. Low risk 5000.00 2022 / 2 / 17 2023 / 1 / 17 5.30%
Wangsu Science & Technology Co.Ltd(300017) Industrial And Commercial Bank Of China Limited(601398) no USD structured deposit low risk 4438.07 2022 / 2 / 18 2023 / 2 / 17 2.00%
The subsidiary Xinhan financial investment has no RP products, with low risk of 0.06-0.50%
The subsidiary Xinhan financial investment has no RP products, with low risk of 0.16-0.70%
The subsidiary Xinhan financial investment has no RP products, with low risk of 0.11-0.95%
Subsidiary KB securities has no RP products, with low risk of 0.33-1.10%
Subsidiary KB securities has no RP products, with low risk of 1.93-0.85%
Subsidiary KB securities has no usdrp products, with low risk of 0.21-0.30%
Subsidiary KB securities has no usdrp products, with low risk of 0.57-0.55%. Note:
1. For T + 1 low-risk financial products with no termination date indicated in the above table, the specific rate of return shall be subject to the announcement on the official website of the trust. The financial products of BNP Paribas and Citibank with no rate of return specified in the above table are principal guaranteed floating income structured deposits. The final income of the products is related to the performance of the linked subject matter. RP products and usdrp products are t + 0 low-risk financial products, The company applies for purchase and redemption according to its own fund use plan.
2. It refers to the cumulative amount of financial income of RP products and usdrp products into financial principal from December 18, 2021 to February 21, 2022.
3. The subscription amount of foreign currency financial products shall be converted into RMB according to the central exchange rate of the people's Bank of China on February 21, 2022.
2、 Investment risk analysis and risk control measures
1. Investment risk
(1) Most of the authorized amount of financial products purchased by the company are low-risk financial products, and a small number are low-risk or medium-risk financial products. However, the financial market is greatly affected by macro-economy, so it is not excluded that the investment is affected by market fluctuations;
(2) The company and its subsidiaries will timely and appropriately intervene according to the economic situation and changes in the financial market, so the actual income of short-term investment is unpredictable;
(3) Operational risks of relevant staff.
2. For investment risks, the proposed measures are as follows:
(1) The board of directors requests the general meeting of shareholders to authorize the general manager of the company or his authorized person to be responsible for organizing the implementation within the above investment limit. The relevant personnel of the Finance Department of the company will timely analyze and track the progress of the project. If the evaluation finds that there are risk factors that may affect the safety of the company's funds, they will take corresponding measures in time to control the investment risk;
(2) The internal audit department of the company is responsible for internal supervision and regularly conduct comprehensive inspection on the invested financial products;
(3) Independent directors and the board of supervisors have the right to supervise and inspect the use of funds, and can hire professional institutions to audit if necessary;
(4) The company will do a good job in accordance with the relevant provisions of Shenzhen Stock Exchange
